Incidence of low and high-energy fractures in persons with and without HIV infection: A Danish population-based cohort study

AIDS

Volumn 26, Issue 3, 2012, Pages 285-293

  Hansen, Ann Brit E ^a   Gerstoft, Jan ^a   Kronborg, Gitte ^b   Larsen, Carsten S ^c   Pedersen, Court ^d   Pedersen, Gitte ^c   Obel, Niels ^a  

^a Rigshospitalet   (Denmark)

^b Mental Health Services CPH   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

antiretroviral treatment; fractures; HIV; low energy fracture

Indexed keywords

EFAVIRENZ; TENOFOVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; FEMALE; FRACTURE; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK FACTOR; SMOKING;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BONE DISEASES, METABOLIC; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; COMORBIDITY; DENMARK; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; OSTEOPOROSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SMOKING;

EID: 84855348340     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32834ed8a7     Document Type: Article

References (34)

1. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review 1. AIDS 2006; 20:2165-2174. (Pubitemid 44684707)
2. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, MillerMD, et al. Efficacy and safety of tenofovir DF vs. stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292:191-201. (Pubitemid 38917996)
3. Hansen AB, Obel N, Nielsen H, Pedersen C, Gerstoft J. Bone mineral density changes in protease inhibitor-sparing vs. nucleoside reverse transcriptase inhibitor-sparing highly active antiretroviral therapy: data from a randomized trial. HIV Med 2011; 12:157-165.
4. McComsey GA, Kitch D, Daar ES, Tierney C, Jahed NC, Tebas P, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: AIDS Clinical Trials Group A5224 s, a substudy of ACTG A5202. J Infect Dis 2011; 203:1791-1801.
5. Bolland MJ, Grey AB, Horne AM, Briggs SE, Thomas MG, Ellis-Pegler RB, et al. Bone mineral density remains stable in HAART-treated HIV-infected men over 2 years 1. Clin Endocrinol (Oxf) 2007; 67:270-275. (Pubitemid 47076305)
6. Nolan D, Upton R, McKinnon E, John M, James I, Adler B, et al. Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir. AIDS 2001; 15:1275-1280. (Pubitemid 32592360)
7. Brown TT, McComsey GA, King MS, Qaqish RB, Bernstein BM, da Silva BA. Loss of bone mineral density after antiretroviral therapy initiation: independent of antiretroviral regimen. J Acquir Immune Defic Syndr 2009; 51:554-561.
8. Duvivier C, Kolta S, Assoumou L, Ghosn J, Rozenberg S, Murphy RL, et al. Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. AIDS 2009; 27:817-824.
9. van Vonderen MG, Lips P, van Agtmael MA, Hassink EA, Brinkman K, Geerlings SE, et al. First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir. AIDS 2009; 23:1367-1376.
10. Grijsen ML, Vrouenraets SM, Steingrover R, Lips P, Reiss P, Wit FW, et al. High prevalence of reduced bone mineral density in primary HIV-1-infected men. AIDS 2010; 24:2233-2238.
11. Mulligan K, Glidden D, Gonzales P, Ramirez-Cardich M-E, Liu A, Namwongprom S, et al. Effect of FTC/TDF on bone mineral density in seronegative men from 4 continents: DEXA results from the iPrEx Study [Abstract]. 18th Conference on Retroviruses and Opportunistic Infections Boston, MA, USA, February 2011.
12. Triant VA, Brown TT, Lee H, Grinspoon SK. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab 2008; 93:3499-3504.
13. Womack JA, Goulet JL, Gibert C, Brandt C, Chang CC, Gulanski B, et al. Increased risk of fragility fractures among HIV infected compared to uninfected male veterans. PLoS One 2011; 6:e17217.
14. Young B, Dao CN, Buchacz K, Baker R, Brooks JT. Increased rates of bone fracture among HIV-infected persons in the HIV Outpatient Study (HOPS) compared with the US general population, 2000-2006. Clin Infect Dis 2011; 52:1061-1068.
15. Arnsten JH, Freeman R, Howard AA, Floris-Moore M, Lo Y, Klein RS. Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection. AIDS 2007; 21:617-623.
16. Yin MT, Shi Q, Hoover DR, Anastos K, Sharma A, Young M, et al. Fracture incidence in HIV-infected women: results from the Women's Interagency HIV Study. AIDS 2010; 24:2679-2686.
17. Bedimo R, Zhang S, Drechsler H, Tebas R, Maalouf N. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents [Abstract]. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 2011 Rome Italy 2011.
18. Obel N, Engsig FN, Rasmussen LD, Larsen MV, Omland LH, Sorensen HT. Cohort profile: the Danish HIV cohort study. Int J Epidemiol 2009; 38:1202-1206.
19. Lohse N, Hansen A, Jensen-Fangel S, Kronborg G, Kvinesdal B, Larsen CS, et al. Demographics of HIV-1 infection in Denmark: results from The Danish HIV Cohort Study. Scand J Infect Dis 2005; 37:338-343. (Pubitemid 40691514)
20. Frank L. Epidemiology. When an entire country is a cohort. Science 2000; 287:2398-2399. (Pubitemid 30185417)
21. Andersen TF, Madsen M, Joørgensen J, Mellemkjær L, Olsen JH. The Danish Hospital Register: a valuable source of data for modern health sciences. Dan Med Bull 1999; 46:263-268. (Pubitemid 29299976)
22. Lippuner K, Golder M, Greiner R. Epidemiology and direct medical costs of osteoporotic fractures in men and women in Switzerland. Osteoporos Int 2005; 16 (Suppl 2): S8-S17. (Pubitemid 46232116)
23. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation 3. J Chronic Dis 1987; 40:373-383. (Pubitemid 17055592)
24. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data.Med Care 2005; 43:1130-1139. (Pubitemid 41587600)
25. Hansen AB, Gerstoft J, Kronborg G, Pedersen C, Sorensen HT, Obel N. Mortality in siblings of patients coinfected with HIV and hepatitis C virus 1. J Infect Dis 2007; 195:230-235. (Pubitemid 46080055)
26. Satagopan JM, Ben-Porat L, Berwick M, Robson M, Kutler D, Auerbach AD. A note on competing risks in survival data analysis. Br J Cancer 2004; 91:1229-1235. (Pubitemid 39424779)
27. Brown TT, McComsey GA. Association between initiation of antiretroviral therapy with efavirenz and decreases in 25-hydroxyvitamin D. Antivir Ther 2010; 15:425-429.
28. Welz T, Childs K, Ibrahim F, Poulton M, Taylor CB, Moniz CF, et al. Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase. AIDS 2010; 24:1923-1928.
29. Weis N, Lindhardt BO, Kronborg G, Hansen AB, Laursen AL, Christensen PB, et al. Impact of hepatitis C virus coinfection on response to highly active antiretroviral therapy and outcome in HIV-infected individuals: a nationwide cohort study. Clin Infect Dis 2006; 42:1481-1487.
30. Hansen AB, Lohse N, Gerstoft J, Kronborg G, Laursen A, Pedersen C, et al. Cause-specific excess mortality in siblings of patients co-infected with HIV and hepatitis C virus. PLoS One 2007; 2:e738.
31. Saves M, Chene G, Ducimetiere P, Leport C, Le Moal G, Amouyel P, et al. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis 2003; 37:292-298. (Pubitemid 36930361)
32. Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet 2011; 377:1276-1287.
33. Nickelsen TN. Data validity and coverage in the Danish National Health Registry. A literature review. Ugeskr Laeger 2001; 164:33-37. (Pubitemid 34065463)
34. Hoidrup S, Gronbaek M, Gottschau A, Lauritzen JB, Schroll M. Alcohol intake, beverage preference, and risk of hip fracture in men and women. Copenhagen Centre for Prospective Population Studies. Am J Epidemiol 1999; 149:993-1001. (Pubitemid 29246863)